Autolus Therapeutics plc, a clinical-stage biopharmaceutical firm, has appointed Dr. Matthias Will as the new Chief Development Officer effective September 30, 2024. With a wealth of experience in pharmaceutical product development, Dr. Will brings his expertise in achieving regulatory milestones and marketing approvals. His previous roles include Chief Medical Officer at Dren Bio, Inc., Vice President of Clinical Development at CRISPR Therapeutics, and various leadership positions at CytomX Therapeutics, Gilead Sciences, Inc., and Novartis Oncology. This key appointment comes as Autolus prepares to commercialize its first product, obe-cel, for the treatment of relapsed/refractory adult B-ALL. Autolus is looking to expand its pipeline of T cell therapies into other oncology and autoimmune indications. The FELIX trial results for obe-cel have been submitted to regulatory authorities in the US, EU, and the UK, with decisions expected in late 2024. Autolus’ innovative technologies aim to engineer highly effective T cell therapies designed to eliminate cancer and autoimmune diseases.
Biopharmaceutical, Clinical Trials,United Kingdom, United States, Europe
https://www.synconaltd.com/news-and-insights/news/autolus-therapeutics-announces-appointment-of-matthias-will-m-d-as-chief-development-officer/